Pulmonary Arterial Hypertension (Cardiovascular) - Drugs In Development, 2021

July 2021 | 426 pages | ID: PBD4A1F14F60EN
Global Markets Direct

Abstracts

Pulmonary Arterial Hypertension (Cardiovascular) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Drugs In Development, 2021, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 10, 12, 19, 1, 45, 11 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 8 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Pulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Therapeutics Development
Pulmonary Arterial Hypertension - Therapeutics Assessment
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
Pulmonary Arterial Hypertension - Drug Profiles
Pulmonary Arterial Hypertension - Dormant Projects
Pulmonary Arterial Hypertension - Discontinued Products
Pulmonary Arterial Hypertension - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Pulmonary Arterial Hypertension, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pulmonary Arterial Hypertension - Pipeline by Aadi Bioscience Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Abivax SA, 2021
Pulmonary Arterial Hypertension - Pipeline by Acceleron Pharma Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Advent Therapeutics Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Aeon Respire Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Aerami Therapeutics Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, 2021
Pulmonary Arterial Hypertension - Pipeline by Aerovate Therapeutics Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by AI Therapeutics Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Algorithm Sciences Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Altavant Sciences Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Alterras Therapeutics GmbH, 2021
Pulmonary Arterial Hypertension - Pipeline by Apaxen, 2021
Pulmonary Arterial Hypertension - Pipeline by APEIRON Biologics AG, 2021
Pulmonary Arterial Hypertension - Pipeline by Apollo Therapeutics LLC, 2021
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Aqualung Therapeutics Corp, 2021
Pulmonary Arterial Hypertension - Pipeline by AstraZeneca Plc, 2021
Pulmonary Arterial Hypertension - Pipeline by ATXA Therapeutics Ltd, 2021
Pulmonary Arterial Hypertension - Pipeline by Bayer AG, 2021
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, 2021
Pulmonary Arterial Hypertension - Pipeline by Biogen Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Biozeus Pharmaceutical SA, 2021
Pulmonary Arterial Hypertension - Pipeline by Boehringer Ingelheim International GmbH, 2021
Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Co, 2021
Pulmonary Arterial Hypertension - Pipeline by C4X Discovery Holdings Plc, 2021
Pulmonary Arterial Hypertension - Pipeline by Camurus AB, 2021
Pulmonary Arterial Hypertension - Pipeline by Capricor Therapeutics Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Celon Pharma SA, 2021
Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, 2021
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Centessa Pharmaceuticals Plc, 2021
Pulmonary Arterial Hypertension - Pipeline by Cereno Scientific AB, 2021
Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, 2021
Pulmonary Arterial Hypertension - Pipeline by Corsair Pharma Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Denovo Biopharma LLC, 2021
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Co, 2021
Pulmonary Arterial Hypertension - Pipeline by Excubio Pharmaceuticals Inc, 2021
Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, 2021
Pulmonary Arterial Hypertension - Dormant Projects, 2021
Pulmonary Arterial Hypertension - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pulmonary Arterial Hypertension, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021